Bionized Nanoferrite Particles Alter the Course of Experimental Cryptococcus neoformans Pneumonia.

Animals Cryptococcosis / drug therapy Cryptococcus neoformans Inflammation Mice Tumor Necrosis Factor-alpha
cryptococcal pneumonia immune system iron oxide nanoparticles

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
19 04 2022
Historique:
pubmed: 17 3 2022
medline: 22 4 2022
entrez: 16 3 2022
Statut: ppublish

Résumé

Cryptococcosis is a devastating fungal disease associated with high morbidity and mortality even when treated with antifungal drugs. Bionized nanoferrite (BNF) nanoparticles are powerful immunomodulators, but their efficacy for infectious diseases has not been investigated. Administration of BNF nanoparticles to mice with experimental cryptococcal pneumonia altered the outcome of infection in a dose response manner as measured by CFU and survival. The protective effects were higher at lower doses, with reductions in IL-2, IL-4, and TNF-α, consistent with immune modulation whereby reductions in inflammation translate into reduced host damage, clearance of infection, and longer survival.

Identifiants

DOI: 10.1128/aac.02399-21 PMID: 35293784 PMC: PMC9017294
pubmed: 35293784
doi: 10.1128/aac.02399-21
pmc: PMC9017294
doi:

Substances chimiques

Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0239921

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI152078
Pays : United States
Organisme : HHS | National Institutes of Health (NIH)
ID : AI15207
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL059842
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI052733
Pays : United States

Références

Biol Aujourdhui. 2012;206(4):249-61
pubmed: 23419252
mBio. 2016 Jan 26;7(1):e01906-15
pubmed: 26814182
Pediatrics. 2001 May;107(5):E66
pubmed: 11331716
Clin Microbiol Rev. 1999 Oct;12(4):501-17
pubmed: 10515900
Sci Adv. 2020 Mar 25;6(13):eaay1601
pubmed: 32232146
Theranostics. 2015 Sep 01;5(11):1249-63
pubmed: 26379790
Cold Spring Harb Perspect Med. 2014 Jul 01;4(7):a019760
pubmed: 24985132
Infect Immun. 1998 Jan;66(1):89-97
pubmed: 9423844
Int J Nanomedicine. 2017 May 10;12:3617-3636
pubmed: 28553103
Int J Nanomedicine. 2010 Aug 09;5:533-47
pubmed: 20957115
Clujul Med. 2016;89(2):216-9
pubmed: 27152071
Antibiotics (Basel). 2018 Jun 09;7(2):
pubmed: 29890753
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14265-70
pubmed: 18809927
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
Annu Rev Pathol. 2014;9:219-38
pubmed: 24050625
Nanomedicine (Lond). 2011 Sep;6(7):1175-88
pubmed: 21675859
Int J Nanomedicine. 2014 Dec 15;9 Suppl 2:195-205
pubmed: 25565837
Antimicrob Agents Chemother. 1998 Jun;42(6):1437-46
pubmed: 9624491
Exp Biol Med (Maywood). 2016 May;241(10):1064-73
pubmed: 27229901
mSphere. 2019 Aug 7;4(4):
pubmed: 31391283
Sci Rep. 2018 Mar 20;8(1):4916
pubmed: 29559734
Nanotechnology. 2009 Sep 30;20(39):395103
pubmed: 19726837
Expert Opin Drug Deliv. 2015 Mar;12(3):393-414
pubmed: 25366552
Toxicol Appl Pharmacol. 2016 May 15;299:78-89
pubmed: 26739622
Virulence. 2012 May 1;3(3):329-38
pubmed: 22546902
Sci Rep. 2018 Aug 22;8(1):12557
pubmed: 30135553
Infect Immun. 1980 Aug;29(2):494-9
pubmed: 7216421
Methods. 2013 May 1;60(3):226-31
pubmed: 23623821
J Cereb Blood Flow Metab. 2010 Jan;30(1):15-35
pubmed: 19756021
Nat Nanotechnol. 2016 Nov;11(11):986-994
pubmed: 27668795
Bioconjug Chem. 2008 Jun;19(6):1211-8
pubmed: 18517234
Vaccine. 2004 Nov 25;23(2):258-66
pubmed: 15531045
mBio. 2017 Dec 12;8(6):
pubmed: 29233901
Nat Commun. 2017 Oct 3;8(1):777
pubmed: 28974673
J Clin Microbiol. 1999 Oct;37(10):3204-9
pubmed: 10488178
Adv Drug Deliv Rev. 2020;163-164:65-83
pubmed: 32603814
Vaccine. 2007 Jan 26;25(7):1316-27
pubmed: 17052812
Eur J Immunol. 2008 May;38(5):1404-13
pubmed: 18389478
Toxicol Appl Pharmacol. 2016 May 15;299:70-7
pubmed: 26773813
Biomol Eng. 2001 Oct 15;18(3):69-85
pubmed: 11566599
Drugs. 2015 Sep;75(14):1601-11
pubmed: 26323338

Auteurs

Livia C Liporagi Lopes (LC)

Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Preethi Korangath (P)

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Samuel R Dos Santos (SR)

Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.

Kathleen L Gabrielson (KL)

Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Robert Ivkov (R)

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Mechanical Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
Department of Materials Science and Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland, USA.

Arturo Casadevall (A)

Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
ORCID: 0000-0002-9402-9167

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

Within-subject variation of C-reactive protein and high-sensitivity C-reactive protein: A systematic review and meta-analysis.

Alex Gough, Alice Sitch, Erica Ferris et al.
1.00
C-Reactive Protein Humans Biomarkers Inflammation

Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis.

Yanhui Yang, Ji Li, Yi Wang et al.
1.00
Humans Immune Checkpoint Inhibitors Lung Neoplasms Prognosis Inflammation

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Bionized Nanoferrite Particles Alter the...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Mycoses › Cryptococcose › Bionized Nanoferrite Particles Alter the...
questionsmedicales.fr › Eucaryotes › Champignons › Levures › Cryptococcus › Cryptococcus neoformans › Bionized Nanoferrite Particles Alter the...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Bionized Nanoferrite Particles Alter the...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Bionized Nanoferrite Particles Alter the...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de nécrose tumorale › Facteur de nécrose tumorale alpha › Bionized Nanoferrite Particles Alter the...